Tadalafil Tablet
Product Images NDC 70518-3434

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70518-3434). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Tadalafil 5 mg oral tablets, showing a quantity of 100 tablets. The label includes the brand name Remedy Repack and states the product is Rx only. It lists the NDC number 70518-3434-00 and the manufacturer Ajanta Pharma USA Inc. The label advises to keep medication out of reach of children and references a package insert for directions for use.*

FDA Label Image

Mm2 (Tadalafil 5mg 70518 3434 01)

Packaging label for Tadalafil 5 mg tablet, containing 1 tablet. The label shows the proprietary name Tadalafil with strength 5 mg highlighted on a purple background. It includes manufacturer information for Ajanta Pharma USA Inc. and repackager RemedyRepack Inc., with barcode, QR code, and storage instructions, emphasizing prescription use and child safety.*

FDA Label Image

Tadalafil 5mg 70518 3434 02

Label for Tadalafil 5 mg oral tablets showing a package quantity of 250 tablets. The label indicates it is RX only and includes manufacturer details for Ajanta Pharma USA Inc. It also bears warnings about tablet use and storage instructions. The labeler is RemedyRepack Inc.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing change from baseline in IPSS total score over a 12-week treatment period comparing Tadalafil 5 mg tablets and placebo. The graph plots IPSS score changes on the vertical axis against treatment duration in weeks on the horizontal axis, indicating a greater reduction in IPSS score with Tadalafil over time.*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs presenting blood pressure changes over time comparing tadalafil and placebo. The charts illustrate differences in standing systolic blood pressure, standing diastolic blood pressure, supine systolic blood pressure, and supine diastolic blood pressure over a 96-hour period.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs showing changes in systolic blood pressure over 24 hours post-dose. The top graph depicts standing systolic BP in mmHg and the bottom graph shows supine systolic BP in mmHg. Both compare Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg over time in hours.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting the effect of 20 mg tadalafil with 8 mg doxazosin versus placebo with 8 mg doxazosin on systolic blood pressure (mmHg) over 12 hours. Four data series track systolic BP changes at different dosing times (08:00 and 20:00), showing variations in blood pressure after administration of tadalafil or placebo.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A pharmacokinetic curve showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The graph displays concentration decline over a 120-hour period with error bars indicating variability.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between Tadalafil 5 mg and placebo. The x-axis indicates duration of treatment in weeks, and the y-axis shows change from baseline. The graph illustrates a greater decrease in IPSS score for Tadalafil 5 mg compared to placebo, with significance indicated at p<0.01.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS Total Score over a 12-week treatment duration for Tadalafil 5 mg versus placebo. The graph shows Tadalafil 5 mg consistently lowering the score more than placebo, with differences noted as statistically significant (p<0.01).*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph depicting the mean change from baseline in a variable over 26 weeks of therapy. The graph compares Tadalafil/Finasteride combination treatment with Placebo/Finasteride, showing least-squares treatment differences at 0, 4, 12, and 26 weeks. Statistical significance is indicated with annotations a (p<0.001) and b (p<0.05).*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of tadalafil, the active ingredient in the product. The diagram depicts the molecular arrangement of atoms and bonds characteristic of tadalafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.